newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025

  • Ascentage Pharma Group International (NASDAQ: AAPG, HKEX: 6855) announced its management will attend three investor conferences in December 2025.
  • The Piper Sandler 37th Annual Healthcare Conference fireside chat is scheduled for 9:00 am EST on December 2nd.
  • The Evercore ISI HealthCONx Conference fireside chat is scheduled for 3:50 pm EST on December 3rd.
  • One-on-one meetings are scheduled at the Citi 2025 Global Healthcare Conference on December 4th.
  • Ascentage Pharma is a global commercial-stage biopharmaceutical company focused on cancer therapies including Bcl-2, MDM2-p53, \& next-generation kinase inhibitors.
  • Olverembatinib is the Company's first approved product \& a third-generation BCR-ABL1 inhibitor approved in China for CML patients with T315I mutations or resistance to first/second-generation TKIs.
  • Olverembatinib indications are covered by the China National Reimbursement Drug List (NRDL).
  • The Company is conducting the FDA-cleared POLARIS-2 Phase III trial for Olverembatinib in CML, plus Phase III trials for Ph+ ALL \& SDH-deficient GIST.
  • Lisaftoclax is the Company's second approved product \& a novel Bcl-2 inhibitor approved in China for CLL/SLL patients previously treated with BTK inhibitors.
  • Four global registrational Phase III trials are ongoing for Lisaftoclax: GLORA (combination with BTK inhibitors), GLORA-2 (newly diagnosed CLL/SLL), GLORA-3 (AML), \& GLORA-4 (HR MDS).
  • The GLORA-4 study received simultaneous clearance from the US FDA, EU EMA, \& China CDE.
  • The Company holds global intellectual property rights \& has partnerships with Takeda, AstraZeneca, Merck, Pfizer, \& Innovent.
  • Ascentage Pharma maintains R\&D relationships with Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute, \& the University of Michigan.
  • The press release includes forward-looking statements subject to risks outlined in SEC filings, including Form F-1 \& Form 20-F.